The Colorectal Cancer Report
Colorectal Cancer (CRC) remains one of the most prevalent cancers globally and a major focus for R&D investment as competition intensifies across treatment settings.
This Report Offers Insight Into:
- Key Targets: Discover the key targets being investigated in CRC drug development, categorized by therapeutic class, so you don’t miss where the next wave of innovation is emerging.
- Biomarkers: Explore the most studied biomarkers by trial phase, to stay aligned with evolving patient selection strategies.
- Leading Clinical Assets: Uncover the drugs leading CRC clinical trial activity, so you can benchmark against the assets gaining the most traction.
- Drug Developers: Identify the top developers driving progress across the CRC pipeline, to understand who you’re really competing with.
You May Also Be Interested In…
What is Beacon?
Beacon is the essential intelligence platform for R&D decision-makers working in pharma and biotech, offering unique technology and drug datasets for complex therapeutics and disease areas.
Our market-defining proprietary ontologies, manual data curation, and accurate and comprehensive life science data, provide our customers with unparalleled visibility of the drug, trial and commercial landscape.
This is why 24 of the top 25 pharmaceutical companies trust Beacon to power their critical pipeline, competitive, and commercial decisions.
We’d welcome the opportunity to show you how Beacon can transform your data strategy. Book your personalized demonstration today!
